000			03149nam a22004215i 4500
988			_aSpringer_BiomedLife_2019
999			_c116751 _d116751 _x1
001			116751
003			ES-MaUEC
005			20230110040244.0
006			a||||fo|||| 00| 0
007			cr nn nnnaamaa
008			190913s2019 gw | s |||| 0|eng d
020			_a9783030244248
024	7		_a10.1007/978-3-030-24424-8 _2doi
040			_aES-MaUEC _bspa _cES-MaUEC _dES-MaUEC
050		4	_aRC280.L9 _b2019 EB
245	0	0	_aResistance to Targeted Therapies in Lymphomas _cedited by Ana C. Xavier, Mitchell S. Cairo.
250			_a1st ed. 2019.
264		1	_aCham, Switzerland _bSpringer International Publishing _c2019
300			_a1 recurso en línea (XX, 210 páginas) _b27 ilustraciones, 26 ilustraciones
336			_2rdacontent _aTexto _btxt
337			_2rdamedia _aelectrónico _bc
338			_2rdacarrier _arecurso electrónico _bcr
347			_atext file _bPDF _2rda
490	0		_aResistance to Targeted Anti-Cancer Therapeutics _x2196-5501 _v21
490	0		_aBiomedical and Life Sciences (Springer-11642)
505	0		_aMechanisms of Glucocorticoid Response and Resistance in Lymphoid Malignancies -- Resistance to Monoclonal Antibody Therapeutics in Lymphoma -- Resistance to Antibody-Drug Conjugate -- Resistance to Proteasome Inhibitor Therapy in Non-Hodgkin Lymphoma -- Resistance to Histone Deacetylase Inhibitors in the Treatment of Lymphoma -- Resistance to Bruton's Tyrosine Kinase Signaling Pathway Targeted Therapies -- Resistance to Checkpoint Blockade Inhibitors and Immunomodulatory Drugs -- Resistance to Bispecific T-cell Engagers and Bispecific Antibodies -- Resistance to Chimeric antigen receptor T-cell therapy -- Index.
520	3		_aThis volume will review different classes of "target" drugs that have been developed, approved, or are under investigation in the field of lymphoma therapy. The discussion will not only be on the understanding of the mechanisms of action or clinical response of those agents, but also help the reader to understand the nature of lymphoma biology in patients who relapse or are refractor after exposure to those drugs. Contributors will discuss what is currently known about mechanisms of tumor-related or host-related resistance, and how to overcome this resistance. This understanding is crucial given the dismal outcomes of patients with relapsed or refractory lymphomas. The book provides a unique opportunity to review and reflect on the recent successes and pitfalls of the modern lymphoma therapy era. .
650		7	_2embne _aLinfomas _9668066
700	1		_aXavier, Ana C _eeditor _4edt _4http://id.loc.gov/vocabulary/relators/edt
700	1		_aCairo, Mitchell S _eeditor _4edt _4http://id.loc.gov/vocabulary/relators/edt
776	0	8	_iPrinted edition: _z9783030244231
776	0	8	_iPrinted edition: _z9783030244255
776	0	8	_iPrinted edition: _z9783030244262
856	4	0	_uhttps://go.openathens.net/redirector/universidadeuropea.es?url=https://doi.org/10.1007/978-3-030-24424-8 _zAcceso a este recurso digital (usuarios Universidad Europea de Madrid)
942			_2lcc _cLE
998			_aSI _cm _dz _feng _ggw _h0 _b01/2020 _ek _zSI